170229-13-7

Basic information

• Product Name: 5-Isoxazoleacetic acid, 3-(4-cyanophenyl)-4,5-dihydro-
• CAS NO: 170229-13-7
• Molecular Formula: C12H10N2O3
• Molecular Weight: 230.223
• Mol File: 170229-13-7.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 5-Isoxazoleacetic acid, 3-(4-cyanophenyl)-4,5-dihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Isoxazoleacetic acid, 3-(4-cyanophenyl)-4,5-dihydro-(170229-13-7)
• EPA Substance Registry System: 5-Isoxazoleacetic acid, 3-(4-cyanophenyl)-4,5-dihydro-(170229-13-7)

Safety Data

• Hazardous Substances Data: 170229-13-7(Hazardous Substances Data)

Upstream product

• 625-38-7 but-3-enoic acid 
• 52707-59-2 4-Cyanobenzaldoxime 
• 105-07-7 4-cyanobenzaldehyde 
• 52707-54-7 4-cyanobenzaldehyde oxime 
• 170229-12-6 [3-(4-Cyano-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetic acid methyl ester 
• 123476-70-0 (Z)-4-cyano-N-hydroxybenzimidoyl chloride 

Downstream Products

• 170726-81-5 [3-(4-cyano-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetic acid 
• 181023-08-5 (R)-2-[3-(4-cyanophenyl)-4,5-dihydroisoxazol-5-yl]acetic acid 
• 190446-76-5 (R)-3-{2-[3-(4-{Amino-[(E)-tert-butoxycarbonylimino]-methyl}-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetylamino}-4-phenyl-butyric acid methyl ester 
• 217965-37-2 (S)-2-Benzyloxycarbonylamino-3-{2-[3-(4-carbamimidoyl-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetylamino}-propionic acid methyl ester 
• 190447-31-5 β-[({3-[4-(aminoiminomethyl)phenyl]-4,5-dihydro-5-isoxazolyl}acetyl)amino]-3,4-dihydro-γ-oxo-2(1H)-isoquinolinebutanoic acid 
• 170902-52-0 3-[({3-[4-(aminoiminomethyl)phenyl]-4,5-dihydro-5-isoxazolyl}acetyl)amino]-N-(butoxycarbonyl)-L-alanine 
• 190446-72-1 (S)-2-Butoxycarbonylamino-3-{2-[3-(4-carbamimidoyl-phenyl)-4,5-dihydro-isoxazol-5-yl]-acetylamino}-propionic acid methyl ester 

Relevant articles and documents

Isoxazoline and isoxazole fibrinogen receptor antagonists

This invention relates to novel isoxazolines and isoxazoles which are useful as antagonists of the platelet glycoprotein IIb/IIIa fibrinogen receptor complex or the vitronectin receptor, to pharmaceutical compositions containing such compounds, processes for preparing such compounds, and to methods of using these compounds, alone or in combination with other therapeutic agents, for the inhibition of platelet aggregation, as thrombolytics, and/or for the treatment of thromboembolic disorders.

Bisbenzamidine isoxazoline derivatives as factor Xa inhibitors

Factor Xa is an important serine protease in the blood coagulation cascade. It generates thrombin and holds the central position that links the intrinsic and extrinsic activation mechanism in the final common pathway of coagulation. Therefore, inhibition

Discovery of potent isoxazoline glycoprotein IIb/IIIa receptor antagonists

Using the isoxazoline as a common structural feature, three series of glycoprotein IIb/IIIa receptor antagonists were evaluated, culminating in the discovery of XR299 (30). In an in vitro assay of platelet inhibition, XR299 had an IC50 of 0.24 μM and was a potent antiplatelet agent when dosed intravenously in a canine model. It was shown through X-ray studies of the cinchonidine salt 49 that the receptor required the 5(R)-stereochemistry for high potency. The ethyl ester prodrug of XR299, XR300 (29), was orally active in the dog.